Price T Rowe Associates Inc Igm Biosciences, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 42,864 shares of IGMS stock, worth $49,293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,864
Previous 3,568,999
98.8%
Holding current value
$49,293
Previous $21.8 Million
99.77%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding IGMS
# of Institutions
79Shares Held
16.1MCall Options Held
26.8KPut Options Held
800-
Baker Bros. Advisors LP New York, NY4.1MShares$4.71 Million0.06% of portfolio
-
Siren, L.L.C. New York, NY3.26MShares$3.74 Million0.21% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.39 Million0.36% of portfolio
-
Black Rock Inc. New York, NY883KShares$1.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA876KShares$1.01 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $33.3M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...